The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective ... the great work of the Scorpion team to date, along ...

Scorpion's current pipeline, led by STX-478, our mutant-selective PI3Kα program, consists of three internally discovered clinical product candidates and multiple discovery-stage programs.

Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...

Indianapolis: Eli Lilly and Company and Scorpion Therapeutics, Inc., a private biotechnology company developing small ...

NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.

Eli Lilly (NYSE:LLY) has agreed to buy Scorpion Therapeutics' lead drug program for up to $2.5B in cash and spin out the remaining company as a new entity focused on precision medicine. Scorpion's ...

Scorpion's current pipeline, led by STX-478, our mutant-selective PI3Ka program, consists of three internally discovered clinical product candidates and multiple discovery-stage programs. Our focus is ...

Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase ... We look forward to ...